治疗耐药高血压的最新进展:重点关注内甲素受体对抗剂
Sayeh Heidari Nejad1, Omar Azzam1,2, Markus P Schlaich1,2,3
1Dobney Hypertension Centre, Medical School - Royal Perth Hospital Unit & RPH Research Foundation, The University of Western Australia, Perth, Western Australia, Australia.
Future cardiology
|July 2, 2024
概括
一种新药,阿普罗西坦,有效降低抗高血压患者的血压. 这种双重内甲素受体对抗剂为难以控制的高血压提供了有前途的治疗选择.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学 是一个学科.
背景情况:
- 抗性高血压 (RH) 带来了重大的健康风险,通常由标准疗法管理不充分.
- 内分泌素途径与RH有关,但内分泌素抗剂面临临临床障碍.
- 阿普罗西坦是一种新型的双内分泌素受体对抗剂.
研究的目的:
- 评估阿普罗西坦在治疗耐药高血压中的安全性和有效性.
- 评估阿普罗西坦在血压管理中的长期有效性.
主要方法:
- 在PRECISION试验中,对抗性高血压患者的阿普罗西坦进行了研究.
- 评估了短期和长期的安全性和降低血压的影响.
主要成果:
- 阿普罗西坦被证明具有临床意义和持续的降低血压.
- 这种药物在短期和长期评估中显示出良好的安全性.
- 这导致最近FDA批准了aprocitentan.
结论:
- 阿普罗西坦是抗性高血压的有效和安全治疗方法.
- 它可能对老年患者,患有慢性脏病和白尿的患者特别有益.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700
Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
606
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
606
Antihypertensive Drugs: Vasodilators
503
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503


